In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: Formulation and biological evaluation in animal model.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 25 11 2019
revised: 01 03 2020
accepted: 07 03 2020
pubmed: 14 3 2020
medline: 16 1 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

In-situ forming implants receive great attention for repairing serious bone injuries. The aim of the present study was to prepare novel chitosan in-situ forming implants (CIFI) loaded with bioactive glass nanoparticles and/or raloxifene hydrochloride (RLX). Incorporating raloxifene hydrochloride (RLX) as a selective estrogen receptor modulator was essential to make use of its anti-resorptive properties. The prepared formulae were tested for their in-vitro gelation time, drug release, injectability, rheological properties, erosion rate and morphological properties. Results revealed that the formulation composed of 1% (w/v) chitosan with 2% (w/v) NaHCO

Identifiants

pubmed: 32165229
pii: S0378-5173(20)30197-6
doi: 10.1016/j.ijpharm.2020.119213
pii:
doi:

Substances chimiques

13-93 bioactive glass 0
Bone Density Conservation Agents 0
Drug Carriers 0
Drug Implants 0
Raloxifene Hydrochloride 4F86W47BR6
Chitosan 9012-76-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119213

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Fatma S Abdel-Salam (FS)

Egyptian Patent Office, Academy of Scientific Research and Technology, Cairo, Egypt.

Seham A Elkheshen (SA)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Azza A Mahmoud (AA)

Department of Pharmaceutical Technology, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Cairo, Egypt; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt.

Emad B Basalious (EB)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. Electronic address: emad.basalious@pharma.cu.edu.eg.

Mohammed S Amer (MS)

Department of Surgery, Anaesthesiology and Radiology, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.

Amany A Mostafa (AA)

Department of Refractories, Ceramics and Building Materials, Inorganic Chemical Industries and Mineral Resources Division, Nanomedicine and Tissue Engineering Lab, National Research Centre, Dokki, Cairo, Egypt.

Nermeen A Elkasabgy (NA)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH